Gallbladder Cancer - Pipeline Review, H1 2016 Summary Global Markets Direct's, 'Gallbladder Cancer - Pipeline Review, H1 2016', provides an overview of the Gallbladder Cancer pipeline landscape. The report provides comprehensive information on the therapeutics under development for Gallbladder Cancer, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Gallbladder Cancer and features dormant and discontinued projects. Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis. The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data. Scope - The report provides a snapshot of the global therapeutic landscape of Gallbladder Cancer - The report reviews pipeline therapeutics for Gallbladder Cancer by companies and universities/research institutes based on information derived from company and industry-specific sources - The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages - The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved Gallbladder Cancer therapeutics and enlists all their major and minor projects - The report assesses Gallbladder Cancer therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type - The report summarizes all the dormant and discontinued pipeline projects - The report reviews latest news related to pipeline therapeutics for Gallbladder Cancer Reasons To Buy - Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Identify and understand important and diverse types of therapeutics under development for Gallbladder Cancer - Identify potential new clients or partners in the target demographic - Develop strategic initiatives by understanding the focus areas of leading companies - Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics - Devise corrective measures for pipeline projects by understanding Gallbladder Cancer pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and Scope - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Table of Contents
Table of Contents 2 List of Tables 4 List of Figures 5 Introduction 6 Global Markets Direct Report Coverage 6 Gallbladder Cancer Overview 7 Therapeutics Development 8 Pipeline Products for Gallbladder Cancer - Overview 8 Pipeline Products for Gallbladder Cancer - Comparative Analysis 9 Gallbladder Cancer - Therapeutics under Development by Companies 10 Gallbladder Cancer - Therapeutics under Investigation by Universities/Institutes 11 Gallbladder Cancer - Pipeline Products Glance 12 Clinical Stage Products 12 Gallbladder Cancer - Products under Development by Companies 13 Gallbladder Cancer - Products under Investigation by Universities/Institutes 14 Gallbladder Cancer - Companies Involved in Therapeutics Development 15 4SC AG 15 Array BioPharma Inc. 16 Novartis AG 17 Spectrum Pharmaceuticals, Inc. 18 VasGene Therapeutics, Inc. 19 Gallbladder Cancer - Therapeutics Assessment 20 Assessment by Monotherapy Products 20 Assessment by Target 21 Assessment by Mechanism of Action 23 Assessment by Route of Administration 25 Assessment by Molecule Type 27 Drug Profiles 29 binimetinib - Drug Profile 29 Product Description 29 Mechanism of Action 29 R&D Progress 29 Cellular Immunotherapy to Target CD-3 and HER-2 for Oncology - Drug Profile 34 Product Description 34 Mechanism of Action 34 R&D Progress 34 DKN-01 - Drug Profile 35 Product Description 35 Mechanism of Action 35 R&D Progress 35 resminostat - Drug Profile 37 Product Description 37 Mechanism of Action 37 R&D Progress 37 SPI-1620 - Drug Profile 43 Product Description 43 Mechanism of Action 43 R&D Progress 43 trametinib dimethyl sulfoxide - Drug Profile 45 Product Description 45 Mechanism of Action 45 R&D Progress 45 Vas-01 - Drug Profile 48 Product Description 48 Mechanism of Action 48 R&D Progress 48 Gallbladder Cancer - Recent Pipeline Updates 50 Gallbladder Cancer - Dormant Projects 61 Gallbladder Cancer - Discontinued Products 62 Appendix 63 Methodology 63 Coverage 63 Secondary Research 63 Primary Research 63 Expert Panel Validation 63 Contact Us 63 Disclaimer 64
List of Tables
Number of Products under Development for Gallbladder Cancer, H1 2016 8 Number of Products under Development for Gallbladder Cancer - Comparative Analysis, H1 2016 9 Number of Products under Development by Companies, H1 2016 10 Number of Products under Investigation by Universities/Institutes, H1 2016 11 Comparative Analysis by Clinical Stage Development, H1 2016 12 Products under Development by Companies, H1 2016 13 Products under Investigation by Universities/Institutes, H1 2016 14 Gallbladder Cancer - Pipeline by 4SC AG, H1 2016 15 Gallbladder Cancer - Pipeline by Array BioPharma Inc., H1 2016 16 Gallbladder Cancer - Pipeline by Novartis AG, H1 2016 17 Gallbladder Cancer - Pipeline by Spectrum Pharmaceuticals, Inc., H1 2016 18 Gallbladder Cancer - Pipeline by VasGene Therapeutics, Inc., H1 2016 19 Assessment by Monotherapy Products, H1 2016 20 Number of Products by Stage and Target, H1 2016 22 Number of Products by Stage and Mechanism of Action, H1 2016 24 Number of Products by Stage and Route of Administration, H1 2016 26 Number of Products by Stage and Molecule Type, H1 2016 28 Gallbladder Cancer Therapeutics - Recent Pipeline Updates, H1 2016 50 Gallbladder Cancer - Dormant Projects, H1 2016 61 Gallbladder Cancer - Discontinued Products, H1 2016 62
List of Figures
Number of Products under Development for Gallbladder Cancer, H1 2016 8 Number of Products under Development for Gallbladder Cancer - Comparative Analysis, H1 2016 9 Number of Products under Development by Companies, H1 2016 10 Comparative Analysis by Clinical Stage Development, H1 2016 12 Assessment by Monotherapy Products, H1 2016 20 Number of Products by Targets, H1 2016 21 Number of Products by Stage and Targets, H1 2016 21 Number of Products by Mechanism of Actions, H1 2016 23 Number of Products by Stage and Mechanism of Actions, H1 2016 23 Number of Products by Routes of Administration, H1 2016 25 Number of Products by Stage and Routes of Administration, H1 2016 25 Number of Products by Molecule Types, H1 2016 27 Number of Products by Stage and Molecule Types, H1 2016 27
Global automotive ECU market is projected to be valued at USD 45.98 billion by 2020, as per a new research report by Radiant Insights, Inc. Rising use in infotainment systems coupled with high deployment in electric vehicles applications is expectedRead More...
Global Biocides market size is likely to be valued at USD 11.9 billion by 2022; as per a new research report by Radiant Insights, Inc. Growth in water treatment process units particularly in China, Japan and India is likely to drive demand. IncreasinRead More...
Global fluorotelomers market size is anticipated to be valued at USD 539.3 million by 2020, as per a new research report by Radiant Insights, Inc. Increasing application scope in fire fighting systems owing to growing safety concerns is likely to driRead More...
Global adhesives & sealants market size is expected to reach USD 43.19 billion by 2020, as per a new research report by Radiant Insights, Inc. Strong demand from packaging, construction and automotive industries is expected drive adhesives and sealanRead More...
Global PP (Polypropylene) nonwoven fabric market size is anticipated to be valued at USD 30.6 billion by 2020, as per a new research report by Radiant Insights, Inc. Growing usage of hygiene products such as incontinence products and baby diapers isRead More...
Get your queries resolved from an industry expert. Request for a free product review before report purchase.
Toll Free: 1-888-928-9744
Email: [email protected]
Speak to the report author to design an exclusive study to serve your research needs.
A testimonial for service excellence represented in the form of BBB "A" Accreditation.
Your personal and confidential information is safe and secure.